BridgeBio Catapults After Snagging Approval For Its Rival To Pfizer's Heart Drug
In This Article:
BridgeBio Pharma snagged FDA approval for its rival to Pfizer's heart disease treatment, Vyndaqel. BridgeBio stock catapulted.
Oops, something went wrong
Unlock stock picks and a broker-level newsfeed that powers Wall Street.
BridgeBio Pharma snagged FDA approval for its rival to Pfizer's heart disease treatment, Vyndaqel. BridgeBio stock catapulted.